SlideShare a Scribd company logo
Beta blockers
for acute
Traumatic brain injury
SAMIR EL ANSARY
Global Critical Care
https://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY
Traumatic brain injury (TBI) is associated with
a systemic hyperadrenergic state.
Through activation of beta adrenoreceptors,
catecholamines may induce
hypermetabolism and increase both cardiac
and cerebral oxygen demands.
Common adverse effects of beta blockers were examined
including clinically significant hypotension, bradycardia,
bronchospasm and congestive heart failure.
The current body of
evidence is suggestive of a
benefit of beta blockers
following TBI.
Traumatic Brain Injury
A hyper-adrenergic state has long been
demonstrated in those patients with severe TBI,
as well as non-traumatic sub-arachnoid
hemorrhage.
This sympathetic hyperactivity may
present anywhere along the continuum; from a
mild and apparently benign SIRS state to
the disruptive and difficult to control
Paroxysmal sympathetic storms (PSS)
The most
severe form of the hyper-adrenergic states, PSS,
presents with paroxysmal sympathetic
system activation and adrenal release of
catecholamines.
These PSS events, with their
associated tachycardia, hypertension, tachypnea,
mydriasis, and diaphoresis, often
resemble those of pheochromocytoma and
Hyperthyroid storms
(Earning them the nickname
“Brain storms”).
Several investigators have evaluated the post-TBI
state (with
regards to the plasma and urinary correlates of a
hyper-adrenergic phenomenon) and
noted a greater than 7-fold increase in
norepinephrine, epinephrine, and their urine
excreted metabolites.
Elevations appear to correlate with significant
increases in
sympathetic hyperactivity and are most
pronounced during the first week following
injury.
Neil-Dwyer and
colleagues published several studies on the hyper-
adrenergic state following intra-cranial
hemorrhage.
Although the majority of these related to patients
with nontraumatic SAH,
the group later published findings in the TBI
population as well.
The authors noted that in
both groups, patients with a clinically and/or
biochemically significant hyper-adrenergic
state appeared to have an increased morbidity and
mortality.
Mechanism involved
included a severe hyper-metabolic state,
myocardial ischemia/infarction, and pulmonary
dysfunction.
Other severely injured patients without TBI lacked
the catecholamine surge and
were noted to have better survival rates.
Administration of beta-blockers (BB) in patients
with severe TBI could
attenuate the hyper-adrenergic response, thereby
decreasing cardiac complications and
improving neurological recovery.
Mortality following
severe TBI has remained unacceptably high. Poor
outcomes are generally attributed to
the severity of the primary brain injury and little (if
any) real progress has been made on
improving survival.
Poor outcomes from severe TBI were not a
consequence of the primary insult that could not
be prevented, but rather a failure to utilize less
“traditional” therapeutic approaches.
By
treating intra-cranial hypertension with a multi-
drug regimen, including scheduled
intravenous metoprolol and clonidine leading to
reduction in arterial inflow
pressure.
Through the use of this protocol, the Lund group
demonstrated a significant
reduction in mortality and improvement in
Glasgow Outcome Scale at six months
By investigating and treating the extra-cranial
manifestations (or non-neurological organ
dysfunction) of severe TBI, these previously
overlooked and harmful secondary insults
become potential avenues for improving survival in
this population.
We recently
demonstrated that exposure to beta-blockers in
patients with severe TBI was associated
with a significant reduction in mortality
This reduction in mortality is
even more impressive when considering
that the BB (+) group was older, more
severely
injured, had higher respiratory and
infectious complications, and had a
lower predicted
survival.
WHICH TBI PATIENTS GET BB?
All TBI patients with:
1) intra-cranial hemorrhage by CTH,
AND
2) persistent hyper-adrenergic state with
paroxysmal tachycardia, tachypnea and
hypertension; may also demonstrate diaphoresis,
mydriasis, agitation
WHICH BB TO USE AND HOW MUCH?
1. Propranolol and labetalol
are lipophilic, penetrate BBB, and exhibit
central &
peripheral actions.
2. Initiate propranolol @ 10 mg PT/PO
q8
3. If no gut access, use labetalol 10-20
mg I.V. q4
4. Utilize labetalol 10-40mg I.V. q2 prn
WHEN TO START AND HOW LONG TO
CONTINUE?
1. Initiate after 24-48 h, adequate
resuscitation.
2. Rule out sepsis, missed injuries, un-
addressed pain prior to initiating BB
3. Continue for at least 14 days.
May wean
as HR remains <100.
WHEN TO START AND HOW LONG TO
CONTINUE?
HOW TO TITRATE BB?
1. Consider titration to a mean HR< 90bpm
and/or improvement in symptom
severity/frequency
2. May also titrate for a return of CVRD to less
than 5%
Geriatric trauma
Numerous studies have documented the
beneficial effects of peri-operative beta
blockade
In patients undergoing non-cardiac surgery. In
addition to a significant reduction in
preoperative cardiac mortality, decreases in long-
term overall mortality, long-term
cardiac mortality, postoperative myocardial
infarction, and postoperative myocardial
ischemia have been demonstrated in patients
receiving beta-blockade in the peri-
operative period.
Geriatric trauma
The current ACC/AHA guidelines recommend
peri-operative beta
blockade as a Class I recommendation for
patients who required use of beta blockers in
the recent past for control of angina,
arrhythmia, or hypertension, and high-risk
patients with findings of ischemia on
preoperative testing undergoing vascular
surgery.
WHICH TRAUMA PATIENTS GET BB?
Use of beta-blockers in patients with (1)
prehospital use of BB, (2) known coronary artery
disease, or (3) age greater than 65 years
should be standard of care.
The College has placed this under the standards for
Patient Safety Practices along with DVT prophylaxis
and peri-operative antibiotics.
WHICH BB TO USE AND HOW
MUCH?
1. If patient is one home BB, this
medication should be restarted initially at ½
dose and
then titrated to full dose as tolerated.
2. If not on BB at home, but patient meets
indications, metoprolol should be utilized.
Start at 12.5-25 mg PO/PT q 12h. Titrate to
HR <80 bpm as BP tolerates.
WHICH BB TO USE AND HOW
MUCH?
3. If metoprolol proves ineffective,
propranolol can be utilized. Initiate @ 10
mg PT/PO q
8h.
4. If no gut access, use labetalol 10-20 mg
I.V. q 4h or metoprolol 5-10 mg I.V. q 4h
GOOD LUCK
SAMIR EL ANSARY
ICU PROFESSOR
AIN SHAMS
CAIRO
elansarysamir@yahoo.com
Global Critical Care
https://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY

More Related Content

What's hot

MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
Praveen Nagula
 
Beta blockers in cardiology
Beta blockers in cardiologyBeta blockers in cardiology
Beta blockers in cardiology
Saikumar Dunga
 
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
Dr. onn akbar ali heart specialist kpj kajang   heart failure and beta blockerDr. onn akbar ali heart specialist kpj kajang   heart failure and beta blocker
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
Onn Akbar Ali MBBS ; FRACP; FCSANZ
 
Esmolol in Sepsis
Esmolol in SepsisEsmolol in Sepsis
Esmolol in Sepsis
NIICS
 
Influence B Blocker Mch Augustus 2008 1
Influence B Blocker Mch Augustus 2008 1Influence B Blocker Mch Augustus 2008 1
Influence B Blocker Mch Augustus 2008 1
NadSamm
 
Heart Failure biomarkers
Heart Failure biomarkersHeart Failure biomarkers
Heart Failure biomarkers
drucsamal
 
BCC4: Pierre Janin on Targets in Neuro-ICU
BCC4: Pierre Janin on Targets in Neuro-ICUBCC4: Pierre Janin on Targets in Neuro-ICU
BCC4: Pierre Janin on Targets in Neuro-ICU
SMACC Conference
 
Beta Blockers in current cardiovascular practice
Beta Blockers in current cardiovascular practice  Beta Blockers in current cardiovascular practice
Beta Blockers in current cardiovascular practice
Praveen Nagula
 
Role of anticoagulation in neurocritical care jhjk
Role of anticoagulation in   neurocritical care jhjkRole of anticoagulation in   neurocritical care jhjk
Role of anticoagulation in neurocritical care jhjk
Ankit Gajjar
 
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
The success of neurohormonal blockade: looking back – looking forward: Beta-b...The success of neurohormonal blockade: looking back – looking forward: Beta-b...
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
drucsamal
 
Cardiovascular Biomarkers Lecture
Cardiovascular Biomarkers LectureCardiovascular Biomarkers Lecture
Cardiovascular Biomarkers Lecture
Dr Felipe Templo Jr
 
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-reviewNon-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
Simon Daley
 
Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.
Ramachandra Barik
 
Anticoagulation in cardio-embolic stroke : a debate
Anticoagulation in cardio-embolic stroke :  a debateAnticoagulation in cardio-embolic stroke :  a debate
Anticoagulation in cardio-embolic stroke : a debate
Dr. Tushar Patil
 
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and AblationDabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
larriva
 
Biomarkers in heart failure
Biomarkers in heart failureBiomarkers in heart failure
Biomarkers in heart failure
Himanshu Rana
 
Newer antiarrhythmics
Newer antiarrhythmicsNewer antiarrhythmics
Newer antiarrhythmics
Sunil Reddy D
 
Role of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACSRole of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACS
PERKI Pekanbaru
 
Treatment of Myocardial Infarction
Treatment of Myocardial InfarctionTreatment of Myocardial Infarction
Treatment of Myocardial Infarction
SudirVigneshwar
 
Antiplatelets in stroke recent scenario
Antiplatelets in stroke recent scenarioAntiplatelets in stroke recent scenario
Antiplatelets in stroke recent scenario
NeurologyKota
 

What's hot (20)

MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
 
Beta blockers in cardiology
Beta blockers in cardiologyBeta blockers in cardiology
Beta blockers in cardiology
 
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
Dr. onn akbar ali heart specialist kpj kajang   heart failure and beta blockerDr. onn akbar ali heart specialist kpj kajang   heart failure and beta blocker
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
 
Esmolol in Sepsis
Esmolol in SepsisEsmolol in Sepsis
Esmolol in Sepsis
 
Influence B Blocker Mch Augustus 2008 1
Influence B Blocker Mch Augustus 2008 1Influence B Blocker Mch Augustus 2008 1
Influence B Blocker Mch Augustus 2008 1
 
Heart Failure biomarkers
Heart Failure biomarkersHeart Failure biomarkers
Heart Failure biomarkers
 
BCC4: Pierre Janin on Targets in Neuro-ICU
BCC4: Pierre Janin on Targets in Neuro-ICUBCC4: Pierre Janin on Targets in Neuro-ICU
BCC4: Pierre Janin on Targets in Neuro-ICU
 
Beta Blockers in current cardiovascular practice
Beta Blockers in current cardiovascular practice  Beta Blockers in current cardiovascular practice
Beta Blockers in current cardiovascular practice
 
Role of anticoagulation in neurocritical care jhjk
Role of anticoagulation in   neurocritical care jhjkRole of anticoagulation in   neurocritical care jhjk
Role of anticoagulation in neurocritical care jhjk
 
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
The success of neurohormonal blockade: looking back – looking forward: Beta-b...The success of neurohormonal blockade: looking back – looking forward: Beta-b...
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
 
Cardiovascular Biomarkers Lecture
Cardiovascular Biomarkers LectureCardiovascular Biomarkers Lecture
Cardiovascular Biomarkers Lecture
 
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-reviewNon-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
Non-Specific Intra-Ventricular Conduction Delay - A quick-lit-review
 
Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.
 
Anticoagulation in cardio-embolic stroke : a debate
Anticoagulation in cardio-embolic stroke :  a debateAnticoagulation in cardio-embolic stroke :  a debate
Anticoagulation in cardio-embolic stroke : a debate
 
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and AblationDabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
 
Biomarkers in heart failure
Biomarkers in heart failureBiomarkers in heart failure
Biomarkers in heart failure
 
Newer antiarrhythmics
Newer antiarrhythmicsNewer antiarrhythmics
Newer antiarrhythmics
 
Role of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACSRole of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACS
 
Treatment of Myocardial Infarction
Treatment of Myocardial InfarctionTreatment of Myocardial Infarction
Treatment of Myocardial Infarction
 
Antiplatelets in stroke recent scenario
Antiplatelets in stroke recent scenarioAntiplatelets in stroke recent scenario
Antiplatelets in stroke recent scenario
 

Similar to Beta blockers in brain injuries

Beta blockers in brain injuries
Beta blockers in brain injuriesBeta blockers in brain injuries
Beta blockers in brain injuries
Dr. Mohamed Maged Kharabish
 
Evidence Based Review CHF
Evidence Based Review CHFEvidence Based Review CHF
Evidence Based Review CHF
mdmendoz
 
Intracranial hemorrhage and intracranial hypertension
Intracranial hemorrhage and intracranial hypertensionIntracranial hemorrhage and intracranial hypertension
Intracranial hemorrhage and intracranial hypertension
Trường Sơn
 
Traumatic brain injury lecture g
Traumatic brain injury lecture gTraumatic brain injury lecture g
Traumatic brain injury lecture g
riyadAlmogahed
 
TRAUMATIC BRAIN INJURY
TRAUMATIC BRAIN INJURYTRAUMATIC BRAIN INJURY
TRAUMATIC BRAIN INJURY
logon2kingofkings
 
Traumatic brain injury lecture g
Traumatic brain injury lecture gTraumatic brain injury lecture g
Traumatic brain injury lecture g
riyadAlmogahed
 
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیستFrom vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
ramtinyoung
 
betablocker post MI clinical trial , for herat faliure with presered EF
betablocker post MI clinical trial , for herat faliure with presered EFbetablocker post MI clinical trial , for herat faliure with presered EF
betablocker post MI clinical trial , for herat faliure with presered EF
emergencyislamic
 
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
tsotsolis
 
Managing heart failure in eldery presentation
Managing heart failure in eldery presentationManaging heart failure in eldery presentation
Managing heart failure in eldery presentation
indanasp
 
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
Dr Sushil Gyawali
 
Established uses of beta blockers
Established uses of beta blockersEstablished uses of beta blockers
Established uses of beta blockers
Ramachandra Barik
 
HTN & CVA.pptx
HTN & CVA.pptxHTN & CVA.pptx
HTN & CVA.pptx
ParikshitMishra15
 
Beta blockers
Beta blockers Beta blockers
Beta blockers
Saikumar Dunga
 
Traumatic brain injury
Traumatic brain injuryTraumatic brain injury
Traumatic brain injury
logon2kingofkings
 
Outpatient medicine, 2005
Outpatient medicine, 2005Outpatient medicine, 2005
Outpatient medicine, 2005
Epy Takoy
 
Stroke hyperacute treatment
Stroke hyperacute treatment Stroke hyperacute treatment
Stroke hyperacute treatment
PS Deb
 
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptxBETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
ssuser7307411
 
Role of beta blocker and statin in primary prevention of cardiovascular disease
Role of beta blocker and statin in primary prevention of cardiovascular diseaseRole of beta blocker and statin in primary prevention of cardiovascular disease
Role of beta blocker and statin in primary prevention of cardiovascular disease
LPS Institute of Cardiology Kanpur UP India
 
Acls Fmi 2009
Acls Fmi 2009Acls Fmi 2009
Acls Fmi 2009
Michael LaCombe
 

Similar to Beta blockers in brain injuries (20)

Beta blockers in brain injuries
Beta blockers in brain injuriesBeta blockers in brain injuries
Beta blockers in brain injuries
 
Evidence Based Review CHF
Evidence Based Review CHFEvidence Based Review CHF
Evidence Based Review CHF
 
Intracranial hemorrhage and intracranial hypertension
Intracranial hemorrhage and intracranial hypertensionIntracranial hemorrhage and intracranial hypertension
Intracranial hemorrhage and intracranial hypertension
 
Traumatic brain injury lecture g
Traumatic brain injury lecture gTraumatic brain injury lecture g
Traumatic brain injury lecture g
 
TRAUMATIC BRAIN INJURY
TRAUMATIC BRAIN INJURYTRAUMATIC BRAIN INJURY
TRAUMATIC BRAIN INJURY
 
Traumatic brain injury lecture g
Traumatic brain injury lecture gTraumatic brain injury lecture g
Traumatic brain injury lecture g
 
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیستFrom vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
 
betablocker post MI clinical trial , for herat faliure with presered EF
betablocker post MI clinical trial , for herat faliure with presered EFbetablocker post MI clinical trial , for herat faliure with presered EF
betablocker post MI clinical trial , for herat faliure with presered EF
 
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
Betablockers and-reduction-of-cardiac-events-in-noncardiac4181
 
Managing heart failure in eldery presentation
Managing heart failure in eldery presentationManaging heart failure in eldery presentation
Managing heart failure in eldery presentation
 
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
Traumatic Brain Injury/ Head injury Management/ Approach to Head injury
 
Established uses of beta blockers
Established uses of beta blockersEstablished uses of beta blockers
Established uses of beta blockers
 
HTN & CVA.pptx
HTN & CVA.pptxHTN & CVA.pptx
HTN & CVA.pptx
 
Beta blockers
Beta blockers Beta blockers
Beta blockers
 
Traumatic brain injury
Traumatic brain injuryTraumatic brain injury
Traumatic brain injury
 
Outpatient medicine, 2005
Outpatient medicine, 2005Outpatient medicine, 2005
Outpatient medicine, 2005
 
Stroke hyperacute treatment
Stroke hyperacute treatment Stroke hyperacute treatment
Stroke hyperacute treatment
 
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptxBETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
 
Role of beta blocker and statin in primary prevention of cardiovascular disease
Role of beta blocker and statin in primary prevention of cardiovascular diseaseRole of beta blocker and statin in primary prevention of cardiovascular disease
Role of beta blocker and statin in primary prevention of cardiovascular disease
 
Acls Fmi 2009
Acls Fmi 2009Acls Fmi 2009
Acls Fmi 2009
 

More from samirelansary

Delerium in icu
Delerium in icuDelerium in icu
Delerium in icu
samirelansary
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
samirelansary
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
samirelansary
 
Ventricular tachycardia
Ventricular tachycardiaVentricular tachycardia
Ventricular tachycardia
samirelansary
 
Gaps in acid base balance in icu
Gaps in acid base balance in icuGaps in acid base balance in icu
Gaps in acid base balance in icu
samirelansary
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
samirelansary
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
samirelansary
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
samirelansary
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
samirelansary
 
Arterial line analysis
Arterial line analysisArterial line analysis
Arterial line analysis
samirelansary
 
X.ray pearls 1
X.ray pearls  1X.ray pearls  1
X.ray pearls 1
samirelansary
 
Update in infectious diseases 1
Update in infectious diseases 1Update in infectious diseases 1
Update in infectious diseases 1
samirelansary
 
Subarachnoid haemorrhage
Subarachnoid haemorrhageSubarachnoid haemorrhage
Subarachnoid haemorrhage
samirelansary
 
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and managementSYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
samirelansary
 
Serotonin syndrome 2
Serotonin syndrome  2Serotonin syndrome  2
Serotonin syndrome 2
samirelansary
 
Principles of mechanical ventilation 2
Principles of mechanical ventilation  2Principles of mechanical ventilation  2
Principles of mechanical ventilation 2
samirelansary
 
New critical care issues 2015 17
New critical care issues 2015 17New critical care issues 2015 17
New critical care issues 2015 17
samirelansary
 
Mixed connective tissue disease
Mixed connective tissue diseaseMixed connective tissue disease
Mixed connective tissue disease
samirelansary
 
Intracranial pressure 2015
Intracranial pressure  2015Intracranial pressure  2015
Intracranial pressure 2015
samirelansary
 
Icu research points 2015 1
Icu research points 2015   1Icu research points 2015   1
Icu research points 2015 1
samirelansary
 

More from samirelansary (20)

Delerium in icu
Delerium in icuDelerium in icu
Delerium in icu
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
 
Ventricular tachycardia
Ventricular tachycardiaVentricular tachycardia
Ventricular tachycardia
 
Gaps in acid base balance in icu
Gaps in acid base balance in icuGaps in acid base balance in icu
Gaps in acid base balance in icu
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
 
Arterial line analysis
Arterial line analysisArterial line analysis
Arterial line analysis
 
X.ray pearls 1
X.ray pearls  1X.ray pearls  1
X.ray pearls 1
 
Update in infectious diseases 1
Update in infectious diseases 1Update in infectious diseases 1
Update in infectious diseases 1
 
Subarachnoid haemorrhage
Subarachnoid haemorrhageSubarachnoid haemorrhage
Subarachnoid haemorrhage
 
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and managementSYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
 
Serotonin syndrome 2
Serotonin syndrome  2Serotonin syndrome  2
Serotonin syndrome 2
 
Principles of mechanical ventilation 2
Principles of mechanical ventilation  2Principles of mechanical ventilation  2
Principles of mechanical ventilation 2
 
New critical care issues 2015 17
New critical care issues 2015 17New critical care issues 2015 17
New critical care issues 2015 17
 
Mixed connective tissue disease
Mixed connective tissue diseaseMixed connective tissue disease
Mixed connective tissue disease
 
Intracranial pressure 2015
Intracranial pressure  2015Intracranial pressure  2015
Intracranial pressure 2015
 
Icu research points 2015 1
Icu research points 2015   1Icu research points 2015   1
Icu research points 2015 1
 

Recently uploaded

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.
drhasanrajab
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 

Recently uploaded (20)

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 

Beta blockers in brain injuries

  • 1. Beta blockers for acute Traumatic brain injury SAMIR EL ANSARY
  • 3. Traumatic brain injury (TBI) is associated with a systemic hyperadrenergic state. Through activation of beta adrenoreceptors, catecholamines may induce hypermetabolism and increase both cardiac and cerebral oxygen demands. Common adverse effects of beta blockers were examined including clinically significant hypotension, bradycardia, bronchospasm and congestive heart failure.
  • 4. The current body of evidence is suggestive of a benefit of beta blockers following TBI.
  • 5. Traumatic Brain Injury A hyper-adrenergic state has long been demonstrated in those patients with severe TBI, as well as non-traumatic sub-arachnoid hemorrhage. This sympathetic hyperactivity may present anywhere along the continuum; from a mild and apparently benign SIRS state to the disruptive and difficult to control Paroxysmal sympathetic storms (PSS)
  • 6. The most severe form of the hyper-adrenergic states, PSS, presents with paroxysmal sympathetic system activation and adrenal release of catecholamines. These PSS events, with their associated tachycardia, hypertension, tachypnea, mydriasis, and diaphoresis, often resemble those of pheochromocytoma and Hyperthyroid storms (Earning them the nickname “Brain storms”).
  • 7. Several investigators have evaluated the post-TBI state (with regards to the plasma and urinary correlates of a hyper-adrenergic phenomenon) and noted a greater than 7-fold increase in norepinephrine, epinephrine, and their urine excreted metabolites. Elevations appear to correlate with significant increases in sympathetic hyperactivity and are most pronounced during the first week following injury.
  • 8. Neil-Dwyer and colleagues published several studies on the hyper- adrenergic state following intra-cranial hemorrhage. Although the majority of these related to patients with nontraumatic SAH, the group later published findings in the TBI population as well. The authors noted that in both groups, patients with a clinically and/or biochemically significant hyper-adrenergic state appeared to have an increased morbidity and mortality.
  • 9. Mechanism involved included a severe hyper-metabolic state, myocardial ischemia/infarction, and pulmonary dysfunction. Other severely injured patients without TBI lacked the catecholamine surge and were noted to have better survival rates. Administration of beta-blockers (BB) in patients with severe TBI could attenuate the hyper-adrenergic response, thereby decreasing cardiac complications and improving neurological recovery.
  • 10. Mortality following severe TBI has remained unacceptably high. Poor outcomes are generally attributed to the severity of the primary brain injury and little (if any) real progress has been made on improving survival. Poor outcomes from severe TBI were not a consequence of the primary insult that could not be prevented, but rather a failure to utilize less “traditional” therapeutic approaches.
  • 11. By treating intra-cranial hypertension with a multi- drug regimen, including scheduled intravenous metoprolol and clonidine leading to reduction in arterial inflow pressure. Through the use of this protocol, the Lund group demonstrated a significant reduction in mortality and improvement in Glasgow Outcome Scale at six months
  • 12. By investigating and treating the extra-cranial manifestations (or non-neurological organ dysfunction) of severe TBI, these previously overlooked and harmful secondary insults become potential avenues for improving survival in this population. We recently demonstrated that exposure to beta-blockers in patients with severe TBI was associated with a significant reduction in mortality
  • 13. This reduction in mortality is even more impressive when considering that the BB (+) group was older, more severely injured, had higher respiratory and infectious complications, and had a lower predicted survival.
  • 14. WHICH TBI PATIENTS GET BB? All TBI patients with: 1) intra-cranial hemorrhage by CTH, AND 2) persistent hyper-adrenergic state with paroxysmal tachycardia, tachypnea and hypertension; may also demonstrate diaphoresis, mydriasis, agitation
  • 15. WHICH BB TO USE AND HOW MUCH? 1. Propranolol and labetalol are lipophilic, penetrate BBB, and exhibit central & peripheral actions. 2. Initiate propranolol @ 10 mg PT/PO q8 3. If no gut access, use labetalol 10-20 mg I.V. q4 4. Utilize labetalol 10-40mg I.V. q2 prn
  • 16. WHEN TO START AND HOW LONG TO CONTINUE? 1. Initiate after 24-48 h, adequate resuscitation. 2. Rule out sepsis, missed injuries, un- addressed pain prior to initiating BB 3. Continue for at least 14 days. May wean as HR remains <100.
  • 17. WHEN TO START AND HOW LONG TO CONTINUE? HOW TO TITRATE BB? 1. Consider titration to a mean HR< 90bpm and/or improvement in symptom severity/frequency 2. May also titrate for a return of CVRD to less than 5%
  • 18. Geriatric trauma Numerous studies have documented the beneficial effects of peri-operative beta blockade In patients undergoing non-cardiac surgery. In addition to a significant reduction in preoperative cardiac mortality, decreases in long- term overall mortality, long-term cardiac mortality, postoperative myocardial infarction, and postoperative myocardial ischemia have been demonstrated in patients receiving beta-blockade in the peri- operative period.
  • 19. Geriatric trauma The current ACC/AHA guidelines recommend peri-operative beta blockade as a Class I recommendation for patients who required use of beta blockers in the recent past for control of angina, arrhythmia, or hypertension, and high-risk patients with findings of ischemia on preoperative testing undergoing vascular surgery.
  • 20. WHICH TRAUMA PATIENTS GET BB? Use of beta-blockers in patients with (1) prehospital use of BB, (2) known coronary artery disease, or (3) age greater than 65 years should be standard of care. The College has placed this under the standards for Patient Safety Practices along with DVT prophylaxis and peri-operative antibiotics.
  • 21. WHICH BB TO USE AND HOW MUCH? 1. If patient is one home BB, this medication should be restarted initially at ½ dose and then titrated to full dose as tolerated. 2. If not on BB at home, but patient meets indications, metoprolol should be utilized. Start at 12.5-25 mg PO/PT q 12h. Titrate to HR <80 bpm as BP tolerates.
  • 22. WHICH BB TO USE AND HOW MUCH? 3. If metoprolol proves ineffective, propranolol can be utilized. Initiate @ 10 mg PT/PO q 8h. 4. If no gut access, use labetalol 10-20 mg I.V. q 4h or metoprolol 5-10 mg I.V. q 4h
  • 23. GOOD LUCK SAMIR EL ANSARY ICU PROFESSOR AIN SHAMS CAIRO elansarysamir@yahoo.com Global Critical Care https://www.facebook.com/groups/1451610115129555/#!/groups/145 1610115129555/ Wellcome in our new group ..... Dr.SAMIR EL ANSARY